TIDES USA Recap
Last week, we attended TIDES USA. More than 130 visitors stopped by our booth or watched our joint presentation, Oligonucleotide Production Capacity Improvement with PolarDry® Electrostatic Drying (ESD) Technology, with Nitto Avecia.
![microscope pointed at white powder in a petri dish](/it-eu/-/media/dam/fluidair/usa/website-images/blog-resources/fa-blog-tides-may-21-2024-1200x627.png?h=627&w=1200&la=it-EU&hash=B1FBD8C0AEED003F7120EDECD8E9E4FF)
23
Mag 24
Last week, we attended TIDES USA. More than 130 visitors stopped by our booth or watched our joint presentation, Oligonucleotide Production Capacity Improvement with PolarDry® Electrostatic Drying (ESD) Technology, with Nitto Avecia.
Here are a few of the key themes we heard about the challenges facing oligonucleotide and peptide producers during the show.
- • The product development and launch process is faster than it’s ever been. Getting to market fast offers critical advantages for establishing market leadership and realizing ROI.
- • Thermally sensitive peptide and oligonucleotide technologies offer exciting breakthroughs, but they require different manufacturing processes and regulatory considerations to bring to market.
- • Scaling from laboratory to production scale can be challenging and slow down the product introduction timeline.
These are the challenges that new technologies like Polar Dry® electrostatic drying can help therapeutics manufacturers solve. Electrostatic Drying technology offers a solution to improve the production capacity of oligonucleotides without sacrificing yield in large-scale production.
Did you miss the show? It’s not too late to get the highlights from our joint presentation and talk about your challenges. Simply email us to schedule a time that works for you.